Cellectis S.A. (NASDAQ:CLLS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Cellectis S.A. (NASDAQ:CLLS) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $7.00.

Several equities analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research note on Friday, July 17th. Barclays assumed coverage on Cellectis in a report on Thursday, May 28th. They issued an “overweight” rating and a $9.00 target price for the company.

Institutional Investors Weigh In On Cellectis

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Global Retirement Partners LLC purchased a new position in shares of Cellectis during the fourth quarter worth approximately $34,000. Lido Advisors LLC purchased a new stake in Cellectis in the 1st quarter valued at $32,000. Virtu Financial LLC purchased a new stake in Cellectis in the 3rd quarter valued at $72,000. Acadian Asset Management LLC boosted its stake in Cellectis by 132.9% during the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 26,461 shares during the period. Finally, Millennium Management LLC boosted its stake in Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 22,080 shares during the period. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Stock Down 2.4%

Shares of NASDAQ:CLLS opened at $3.24 on Friday. The company has a market capitalization of $325.10 million, a PE ratio of -4.98 and a beta of 2.92. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.61. Cellectis has a twelve month low of $2.35 and a twelve month high of $5.48. The firm has a 50 day simple moving average of $3.03 and a 200-day simple moving average of $3.38.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%. The firm had revenue of $6.90 million for the quarter, compared to the consensus estimate of $11.05 million.

Cellectis Company Profile

Cellectis is a clinical?stage biopharmaceutical company specializing in the development of gene?edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T?cell (CAR?T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off?the?shelf immunotherapies.